Document is current

Article History

Received: 12 April 2025

Accepted: 11 February 2026

First Online: 11 March 2026

Declarations

:

: This study has been funded by Ferring Pharmaceuticals which is developing follitropin delta. The study sponsor participated in the study design, data collection, analysis and interpretation of data, writing of the manuscript, and in the decision to submit the article for publication.

: Professor Samir Hamamah has received consultancy fees from Ferring Pharmaceuticals and Gedeon Richter, Marie Markert is an employee of Ferring Pharmaceuticals and Jeremy Carette and Henri Leleu have received consultancy fees.

: Not applicable. The study only used previously published data that received ethical approval and consent to participate.

: Not applicable. The study only used previously published data that received ethical approval and consent to participate.

: Not applicable. The study only used previously published data that received ethical approval and consent to participate.

: Ferring Pharmaceuticals A/S will provide access to data upon reasonable request, via a secure portal, to researchers whose proposals meet the research criteria and other conditions, while ensuring compliance to patient privacy regulations. To gain access, data requestors must enter into a data access agreement with Ferring.

: Transmission of the model may be provided upon request with appropriate authorization from Ferring.

: All authors contributed to the design and implementation of the research, to the analysis of the results, and to the writing and validation of the manuscript.